Buy Crypto
Markets
Spot
FuturesBTC
Earn
Event Center
Rewards Hub
More
100%+ PoR
JSPR

Jasper Therapeutics, Inc. (JSPR)

NASDAQ
$11.63
+$1.12
(+10.83%)
Previous Close: ⁦$10.34⁩
Market Closed

Last updated: ⁦2026-11-19 05:33:00⁩. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.

Summary

Jasper Therapeutics, Inc. (JSPR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $11.63, with a market capitalization of $13.06M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9.25 to $72.60. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

$13.06M

$10.67

$11.99

$9.99

$10.34

19.14K

18.16K

--

$72.60

$9.25

--

--

Jasper Therapeutics, Inc. (JSPR) Latest Closing Stock Price

Jasper Therapeutics, Inc. (JSPR) last closed at $11.63 as of 2026-11-19 00:57:00, up 10.83% ($1.12) from the previous close of $10.34.

During the latest regular trading session, JSPR traded between $10.00 and $11.99, with a volume of 19.14K shares. The closing price was near the upper end and near the lower end of its 52-week range.

Jasper Therapeutics, Inc. (JSPR) 7-Day Stock Price Change

Over the past seven days, Jasper Therapeutics, Inc. (JSPR) moved from $16.37 to $11.63, representing a decline of 28.95% ($4.74).

The stock traded between $9.25 and $17.03 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.

The average daily volume was 41.64 thousand shares, up versus the previous seven-day period, indicating higher trading activity.

JSPR 52-Week Price Position

Position in Range: 3.8%

52W Low$9.25
52W High$72.60

JSPR is currently trading at $11.63, placing it 3.8% of the way from its 52-week low of $9.25 to its 52-week high of $72.60. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is Jasper Therapeutics, Inc. (JSPR)?

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Jasper Therapeutics, Inc. Information

Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
22
Exchange
NASDAQ
Company Website

JSPR Stock Events

View the latest dividend and stock split events for Jasper Therapeutics, Inc.

Stock Split
Split DateNov 6, 2026
Split Ratio1-for-30

JSPR News

Latest news related to Jasper Therapeutics, Inc. and JSPR stock.

  • Benzinga

    Update: Jasper Therapeutics Q3 Adj. EPS $(1.05) Beats $(3.00) Estimate, Sales $8.000M Beat $3.000M Estimate

    Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.05) per share which beat the analyst consensus estimate of $(3.00) by 65 percent. This is a 96.73 percent increase over losses of $(32.08) per share

    Read Full Article
  • Benzinga

    Jasper Therapeutics Q3 EPS $(10.19) Misses $(4.80) Estimate, Sales $8.000M Beat $3.000M Estimate

    Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(10.19) per share which missed the analyst consensus estimate of $(4.80) by 112.29 percent. This is a 68.24 percent increase over losses of $(32.08) per

    Read Full Article
  • Massive

    Jasper Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

    Jasper Therapeutics reported Q3 2026 results with $135.3 million in cash following its acquisition of Kira Pharmaceuticals and a $132 million funding round. The company completed enrollment in its Phase 2 IgA nephropathy study for vensobafusp alfa and expanded into additional kidney disease indications including FSGS and IC-MPGN. Interim data from the IgAN cohort is expected in Q4 2026. The company also effected a 1-for-30 reverse stock split and repurchased warrants.

    Read Full Article

Ways to Trade JSPR at MEXC

JSPR MEXC RealStocks

Own real JSPR shares through MEXC's regulated brokerage partner.


Suitable for long-term holding.

  • Own the actual shares
  • Receive dividends and voting rights
  • Buy fractional shares starting at $1

How to Buy Jasper Therapeutics, Inc. (JSPR) Stock on MEXC

Eligible investors can buy real shares of Jasper Therapeutics, Inc. (JSPR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account
Step 1: Open and Verify Your RealStocks Account
Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licensed broker.
Step 2: Transfer USDT to Your RealStocks Account
Step 2: Transfer USDT to Your RealStocks Account
Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.
Step 3: Search for JSPR and Place Your Order
Step 3: Search for JSPR and Place Your Order
Open the RealStocks trading page and search for JSPR. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is Jasper Therapeutics, Inc. (JSPR) stock price today?
Jasper Therapeutics, Inc. (JSPR) is currently trading at $11.63, up 10.83% ($1.12) from the previous close of $10.34. Intraday prices update in real time during regular trading hours.
2.Is JSPR stock going up or down today?
As of 2026-11-19 00:57:00, JSPR is trading at $11.63, up 10.83% ($1.12) from its previous close of $10.34. The stock has traded between $10.00 and $11.99 during today’s regular session. Past price movements do not guarantee future results.
3.What is JSPR pre-market price?
As of 2026-11-19 00:57:00, JSPR is trading at $10.00 in pre-market trading, down 3.34% ($0.35) from the previous close of $10.34. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.
4.What is JSPR after-hours price?
As of 2026-11-19 00:57:00, JSPR is trading at $11.79 in after-hours trading, up 1.34% ($0.16) from the regular-session close of $11.63. After-hours prices may differ from the regular session’s opening price due to lower liquidity and wider bid-ask spreads.
5.Is JSPR stock trading now?
JSPR trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.
6.Where does JSPR sit relative to its 52-week high and low?
Over the past 52 weeks, JSPR has traded between a low of $9.25 and a high of $72.60. At $11.63, the stock is positioned 3.8% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.
7.What sector is Jasper Therapeutics, Inc. in?
Jasper Therapeutics, Inc. (JSPR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.
8.What is Jasper Therapeutics, Inc.'s market capitalization and where is it listed?
Jasper Therapeutics, Inc. is listed on the NASDAQ exchange with a market capitalization of $13.06M. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.
9.How is JSPR valued in terms of P/E ratio and EPS?
JSPR trades at a P/E ratio of --, based on trailing-twelve-month EPS of $-28.62. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.
10.Does Jasper Therapeutics, Inc. pay a dividend?
Jasper Therapeutics, Inc. pays an indicated annual cash dividend of $0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.

Explore More US Stocks

Largest Market Cap

See US stocks with the highest market capitalization

Most Actively Traded

Discover today's most actively traded US stocks

Top 5 Cryptocurrencies

Explore the cryptocurrencies with the highest market capitalization

Compliance Disclosure and Data Source

Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to JSPR, including Stocks, Tokenized Stocks, and Stock Futures.

Disclaimer

The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.

Search Stocks

JSPR Stock Calculator

Estimate the value between JSPR shares and USD.

JSPR Shares to USD

JSPR Shares
JSPR
JSPR
USD
USD
USD

1.00 JSPR shares = 11.631 USD

Calculations are estimates based on the latest available price and are for reference only.